Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : neog - Neogen's E.Coli Test adopted by Japan -- Ignore unavailable to you. Want to Upgrade?

To: Rich H who wrote (381)	10/14/1999 7:40:00 PM
From: Steve Lokness	Respond to of 441

Interesting question. When SDIX was about 2.00 dollars a share, I made this same suggestion on the Yahoo thread. I felt at the time that it would have made an excellent fit for Neogen if the industrial testing was then resold. It is the industrial testing which has been a drain on the profits of SDIX. Since that time SDIX has been rocketing and I don't know how anyone could ever justify the market cap that shareholders would demand. The opportunity may have been missed if in fact it was ever a possibility. You previously asked why NEOG did not make more of a deal of comparing this taxed quarters to previously untaxed ones. I suspect the reason was that for some reason the tax rate decreased in the last quarter to a trifling 9%. Wonder were they found the deducts to bring it back down? The mystery of the numbers. Good Investing! kivtan

To: Rich H who wrote (381)	10/19/1999 11:48:00 AM
From: Kramer	Respond to of 441

Neogen Wins Major USDA Contracts LANSING, Mich., Oct. 19 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG - news) announced today that agencies of the U.S. Department of Agriculture have renewed their trust in Neogen's diagnostics to monitor the safety of the nation's grain and meat supplies. The USDA's Federal Grain Inspection Service (FGIS) awarded Neogen a new contract to use the Company's quantitative test to monitor grain commodities, primarily corn, for aflatoxin. The contract, with the same terms as the initial contract signed in 1994, calls for the exclusive use of Neogen's test at FGIS locations nationwide for the next year, with an option to renew for an additional 4 years thereafter. Similarly, the USDA's Food Safety Inspection Service (FSIS) renewed its 1-year agreement to use Neogen's rapid test for E. coli O157:H7 to screen the nation's meat supply for the deadly bacteria. Neogen's test has earned the use of the FSIS to monitor for E. coli O157:H7 every year since 1994, when Neogen began marketing the test. ``We are obviously quite pleased with the USDA's continued trust in our products' ability to protect consumers,' said Ed Bradley, Neogen's vice president of sales and marketing. ``As substantial as the agreements are with the USDA, their implications are much greater. The continued governmental use retains the tests' 'gold standard' status. Private testers who must comply with government food safety regulations have every reason to use the tests utilized by the regulators themselves.' Aflatoxin, a byproduct of mold growth in grain, is considered by many to be the most potent naturally-occurring carcinogen, and has been linked to a variety of health problems in both humans and animals. Most private food and animal feed companies in the United States routinely test for the presence of this toxic residue in incoming grain supplies, as well as finished food and animal feeds. Government regulation requires all domestic grain shipped outside the United States, or destined for human consumption, contain less than 20 parts per billion of aflatoxin. Neogen Corporation develops and markets products and services dedicated to food and animal safety. The Company's Food Safety Division markets diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases and sanitation concerns. Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward- looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors, including impact of the Year 2000 issue, and factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's most recently filed Form 10-K. SOURCE: Neogen Corporation